| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2006-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008527038-A |
| titleOfInvention |
Mitotic kinesin inhibitor |
| abstract |
The present invention is useful for treating cell proliferative disorders, is useful for treating disorders associated with KSP kinesin activity, and is fluorinated which is useful for inhibiting KSP kinesin. Related to 2-aminomethylthienopyrimidinone compounds. The present invention also relates to compositions comprising these compounds and methods of using these compounds to treat cancer in mammals. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013091660-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013523867-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013525290-A |
| priorityDate |
2005-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |